skip to content

eLesor Investments version="1.1" id="Layer_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 697.5 99.8" style="enable-background:new 0 0 697.5 99.8;" xml:space="preserve" aria-labelledby="title--mwlogoHeader desc--mwlogoHeader" role="img"> eLesor Site Logo A link that brings you back to the homepage.

Sorrento Therapeutics Shares Rise After Receiving UK Authorization for Phase 2 Trial for Covid Nose Drops

By Kimberly Chin

 

Sorrento Therapeutics Inc.'s shares rose 4.3% after hours to $9.25 after UK regulators cleared a Phase 2 study for the company's Covid-19 nasal drops in newly diagnosed Covid-19 patients.

The Phase 2 trial of Covi-Drops will involve around 350 outpatients with Covid-19 who are either asymptomatic or have mild symptoms compared with a placebo.

This will complement trials in the U.S. and a separate trial in Mexico, the biopharmaceutical company said.

The Covi-Drops are intranasal drops that will have antibodies that fight against the Covid-19 virus, as well as some of its new variants.

 

Write to Kimberly Chin at [email protected]




      

Partner Center